Chronic Lymphoblastic Leukemia


Pass It On: July is National Leukemia and Lymphoma Awareness Month (September 1, 2016)

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia... Continue Reading

Venclexta® Approved for Chronic Lymphocytic Leukemia (April 20, 2016)

The United States Food and Drug Administration (FDA) has approved the targeted agent, Venclexta® (venetoclax), for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a specific... Continue Reading

Arzerra® Approved as Maintenance Therapy for Advanced CLL (February 29, 2016)

The United States Food and Drug Administration (FDA) has approved Arzerra® (ofatumumab) as maintenance therapy for the treatment of advanced chronic lymphocytic leukemia (CLL). This product is already... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood... Continue Reading

Gazyva/Chlorambucil Improves Outcomes in Older CLL Patients with Other Health Problems (December 16, 2013)

Among older people with chronic lymphocytic leukemia (CLL) and other health problems, initial treatment with Gazyva® (obinutuzumab) and chlorambucil was more effective than treatment with Rituxan® (rituximab)... Continue Reading

Ibrutinib Active In Untreated, Relapsed and Unresponsive CLL (June 3, 2013)

The drug ibrutinib was well tolerated and highly effective in patients with untreated, relapsed and unresponsive chronic lymphocytic leukemia—leading to large reductions in tumor burden, according to... Continue Reading

Lymphoma Patients and Transplant Recipients at Higher Risk of Melanoma (October 11, 2012)

Individuals with lymphoma or those who have undergone organ transplants are far more likely than the average person to develop—and die from—melanoma, according to the results of a review published... Continue Reading

Caring for Yourself During Chemotherapy for Leukemia: How to Manage Hair Loss, Dry Skin, and Brittle Nails (June 3, 2012)

Chemotherapy can be effective treatment for cancer but may also cause physical side effects that may be uncomfortable and affect your appearance. These side effects, however, are manageable. Hair Loss Hair... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients.... Continue Reading

Survivors of Some Childhood Cancers May Face Cognitive Impairment (May 18, 2010)

Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according... Continue Reading

Arzerra, Fludara, and Cytoxan Promising for Previously Untreated CLL (February 1, 2010)

The combination of Arzerra™ (ofatumumab), Fludara® (fludarabine), and Cytoxan® (cyclophosphamide) shows promising effectiveness in the initial treatment of chronic lymphocytic leukemia (CLL). These... Continue Reading

Treanda® and Rituxan® Effective Initial Therapy for CLL (January 5, 2010)

According to the results of a Phase II clinical trial, the combination of Treanda® (bendamustine) and Rituxan® (rituximab) is effective and safe for the initial treatment of patients with advanced chronic... Continue Reading

Arzerra™ Approved for Refractory Chronic Lymphocytic Leukemia (October 28, 2009)

The targeted therapy Arzerra™ (ofatumumab) has been granted accelerated approval by the U.S. Food and Drug Administration for treatment of patients with chronic lymphocytic leukemia (CLL) that is refractory... Continue Reading

September Is National Leukemia and Lymphoma Awareness Month (August 28, 2009)

As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment... Continue Reading

Formaldehyde Exposure May Increase Risk of Blood and Lymphatic Cancers (June 23, 2009)

Industrial workers who are exposed to formaldehyde may be at an increased risk of dying from blood and lymphatic cancers, particularly myeloid leukemia but also Hodgkin’s lymphoma and multiple myeloma,... Continue Reading

Sequential Treatment with Fludara®, Cytoxan®, and Rituxan® Produces High-quality Responses in CLL (February 24, 2009)

Sequential Treatment with Fludara®, Cytoxan®, and Rituxan® Produces High-quality Responses in CLL Patients with chronic lymphocytic leukemia (CLL) treated with Fludara® (fludarabine), followed by consolidation... Continue Reading

FCR-Lite Is Safe and Effective in Previously Untreated CLL (February 19, 2009)

FCR-Lite Is Safe and Effective in Previously Untreated CLL FCR-Lite, a drug regimen that consists of Fludara® (fludarabine), Cytoxan® (cyclophosphamide), and Rituxan® (rituximab), is highly effective... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS